Yahoo Web Search

Search results

  1. CEPI 2.0 and the 100 Days Mission. CEPIs 2022-2026 strategy, known as CEPI 2.0, will help Prepare, Transform, and Connect the world so that it can respond to the next Disease X threat with a new vaccine in just three months. Read more

    • Who We Are

      CEPI’s 2022-2026 plan, known as CEPI 2.0, will help the...

    • Priority Diseases

      CEPI’s priority pathogens include Chikungunya, COVID-19,...

    • Contact

      CEPI is keen to discuss potential involvement with...

    • Why We Exist

      That vaccine was shown to have 100% efficacy, suggesting...

    • Support CEPI

      CEPI partners with vaccine developers, manufacturers,...

    • Our Portfolio

      CEPI is providing up to US $25 million to advance...

    • Covax

      Seven CEPI-backed vaccines have been approved for use either...

    • 100 Days

      CEPI’s 2022-2026 strategy, known as CEPI 2.0, will help...

    • Vaccine Science

      Launched in 2020 in response to the COVID-19 pandemic,...

    • Platform Technology

      It also co-led COVAX, the global initiative to deliver fair...

  2. 1 day ago · CEPI 28th May 2024. BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa. CEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African ...

  3. CEPI outlined its projects to update CEPI priorities for establishment of technical and regulatory pathways for vaccine development, develop sustainable manufacturing solutions for vaccine candidates nearing completion, and create investigatory stockpiles of its vaccine candidates for use in emergency situations.

  4. Oct 30, 2023 · CEPI has supported the development of over 30 vaccine candidates against its priority pathogens—Chikungunya virus, Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and SARS-CoV-2—and is a leading funder of research into broadly protective coronavirus vaccines, which could protec...

  5. Jul 5, 2022 · CEPI will provide up to US $30 million to support the development of the vaccine through Phase I trials, including preclinical work, with the aim to establish first-in-human clinical proof of concept for the vaccine. The funding will also support the design of the vaccine and regulatory activities.

  1. People also search for